Best of 2025: 5 major changes that redefined cardiology
Industry Buzz
A lot of these trials were started just before or during the pandemic and are just now coming to fruition... We’re seeing the results of several years of work finally pay off.
—B. Hadley Wilson, MD, interventional cardiologist, Cardiovascular Business
After years of steady progress, this year has brought a wave of cardiology breakthroughs—spanning hypertension, prevention, interventional devices, AI, and precision risk targeting—that are already reshaping how cardiovascular specialists think, diagnose, and treat.
Below, five developments that are poised to influence everyday practice sooner rather than later.
1. Novel therapies for hypertension and cardiometabolic risk
A standout is the approval in June 2025 of a triple-combination single-pill therapy (telmisartan + amlodipine + indapamide) for hypertension, marking one of the first major regulatory moves in this area in years.[]
On the prevention front, the latest generation of anti-obesity/GLP-1/dual-agonist drugs are now demonstrating cardiovascular event reduction beyond weight loss. As noted by the American College of Cardiology in Cardiology Magazine, “Undoubtedly, the most talked-about trend today is the latest generation of anti-obesity medications. The two most popular of these increasingly popular drugs – semaglutide and tirzepatide – demonstrate remarkable cardiovascular benefits that extend beyond weight management.”[]
2. Shift in antiplatelet therapy: Clopidogrel vs aspirin
A large meta-analysis presented at the European Society of Cardiology (ESC) 2025 congress found that long-term monotherapy with clopidogrel reduced major adverse cardiovascular or cerebrovascular events by ~14% compared with aspirin, without increasing major bleeding.[]
In lay terms, these results challenge aspirin’s longstanding dominance in secondary prevention. Cardiologists may be interested in reviewing antiplatelet strategies in stable coronary artery disease (CAD) patients, particularly those with prior events, anticipating upcoming guideline revisions.
3. Interventional and structural cardiology: Technology and durability advances
At the Transcatheter Cardiovascular Therapeutics (TCT) 2025 meeting, late-breaking trials highlighted renewed interest in drug-coated balloons (DCBs) for in-stent restenosis and small vessels, as well as long-term durability data for transcatheter aortic valve replacement (TAVR) devices. As interventional cardiologist B. Hadley Wilson, MD, commented, “We’re seeing the results of several years of work finally pay off.”[]
For interventional teams, this means reassessing strategy for small-vessel disease and in-stent restenosis, and it may expand the use of TAVR devices into younger or lower-risk cohorts.
4. AI, digital diagnostics, and remote monitoring enter the mainstream
The ACC review for 2025 also flagged the growth of AI and big-data tools in cardiology: from advanced ECG interpretation using transformer models, to remote monitoring in heart failure, to prediction algorithms.[]
For example, an AI stethoscope developed in the UK has been shown to detect heart failure, valve disease, and arrhythmias in mere seconds.
5. Precision prevention and emerging risk-factor targeting
Beyond standard risk-factor control, cardiology is seeing emerging therapies targeting previously untreatable risks, such as genetic factors. One of these is elevated lipoprotein(a), or Lp(a). In a mid-stage trial, lepodisiran reduced Lp(a) by ~94% over placebo after only one or two doses, opening a potential new avenue for high-risk patients.[]
Additionally, guidelines are defining lifestyle interventions with greater precision (eg, potassium intake, plant-forward diet) and advocating for earlier intervention.[]
Cardiologists should incorporate Lp(a) screening, consider novel therapies as they mature, and expand prevention workflows, especially for high-risk patients with subclinical disease.
In summary, 2025 is shaping up as a pivot-year in cardiology, represented by more aggressive hypertension management, antiplatelet strategy re-thinking, innovations in interventional and structural care, digital-health integration, and precision prevention. Cardiologists and cardiovascular teams will need to adapt protocols, educate patients, and align systems to deliver on these advances.
Read Next: Here's a skill you might have missed in cardiology training: Mind control